NO943101D0 - 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist - Google Patents

2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist

Info

Publication number
NO943101D0
NO943101D0 NO943101A NO943101A NO943101D0 NO 943101 D0 NO943101 D0 NO 943101D0 NO 943101 A NO943101 A NO 943101A NO 943101 A NO943101 A NO 943101A NO 943101 D0 NO943101 D0 NO 943101D0
Authority
NO
Norway
Prior art keywords
methano
receptor antagonist
quinolizine derivative
quinolizine
derivative
Prior art date
Application number
NO943101A
Other languages
English (en)
Norwegian (no)
Other versions
NO943101L (no
Inventor
Maurice Ward Gittos
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NO943101L publication Critical patent/NO943101L/no
Publication of NO943101D0 publication Critical patent/NO943101D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO943101A 1992-02-24 1994-08-23 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist NO943101D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92400474 1992-02-24
PCT/US1993/000880 WO1993017019A1 (en) 1992-02-24 1993-02-03 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist

Publications (2)

Publication Number Publication Date
NO943101L NO943101L (no) 1994-08-23
NO943101D0 true NO943101D0 (no) 1994-08-23

Family

ID=8211614

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943101A NO943101D0 (no) 1992-02-24 1994-08-23 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist

Country Status (14)

Country Link
EP (1) EP0628043A1 (fi)
JP (1) JPH07504192A (fi)
KR (1) KR100287933B1 (fi)
AU (1) AU675060B2 (fi)
CA (1) CA2130563C (fi)
FI (1) FI105917B (fi)
HU (1) HU216831B (fi)
IL (1) IL104821A (fi)
MX (1) MX9300948A (fi)
NO (1) NO943101D0 (fi)
NZ (1) NZ249346A (fi)
TW (1) TW226374B (fi)
WO (1) WO1993017019A1 (fi)
ZA (1) ZA931146B (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537255A (ja) 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト リウマチ性炎症性プロセスに対する５−ｈｔ３レセプターアンタゴニストの全身的使用
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CA2600350C (en) 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE129153T1 (de) * 1988-02-23 1995-11-15 Merrell Dow Pharma Verwendung von chinolizin- und chinolizinon- derivaten zur herstellung von arzneimitteln.
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines

Also Published As

Publication number Publication date
FI943872A (fi) 1994-08-23
FI105917B (fi) 2000-10-31
HUT68249A (en) 1995-06-28
NO943101L (no) 1994-08-23
JPH07504192A (ja) 1995-05-11
ZA931146B (en) 1993-09-14
IL104821A0 (en) 1993-06-10
EP0628043A1 (en) 1994-12-14
AU675060B2 (en) 1997-01-23
WO1993017019A1 (en) 1993-09-02
CA2130563A1 (en) 1993-09-02
AU3603493A (en) 1993-09-13
IL104821A (en) 1997-01-10
KR950700297A (ko) 1995-01-16
HU9402436D0 (en) 1994-10-28
TW226374B (fi) 1994-07-11
HU216831B (hu) 1999-09-28
MX9300948A (es) 1993-08-01
FI943872A0 (fi) 1994-08-23
NZ249346A (en) 1995-10-26
KR100287933B1 (ko) 2001-05-02
CA2130563C (en) 1997-11-11

Similar Documents

Publication Publication Date Title
DK0808312T3 (da) Indolderivater som 5-HT-receptorantagonist
DK0804419T3 (da) Quinolinderivater som tachykinin NK 3-receptor-antagonister
ATE201016T1 (de) Pyrimidindion-, pyrimidintrion-, triazindion- derivate als alpha-1-adrenergische rezeptorantagonisten
NO943348L (no) Kondenserte indolderivater som 5HT4-reseptorantagonister
DK0856001T3 (da) Pyrimidinderivater som 5-HT2C-receptor-antagonister
FI961628A0 (fi) Indolijohdannaisia NMDA-antagonisteina
FI963786A0 (fi) Uusia 1,4-disubstituoituja piperidiinijohdannaisia, jotka ovat käyttökelpoisia glutamaattireseptoriin vaikuttavina lääkeaineina
AU2314195A (en) Benzofuran derivatives as d4 receptor antagonists
DK0854867T3 (da) Tetrahydroquinoliner som NMDA-antagonister
DK0710230T3 (da) Som CCK- eller gastrinantagonister anvendelige 1,5-benzodiazepinderivater
FI951798A0 (fi) Bentsofuraanijohdannaiset 5-HT1-kaltaisina reseptoriantagonisteina
NO985970L (no) Indolinderivater anvendelige som 5_HT-2C-reseptor-antagonister
NO943101D0 (no) 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist
NO985972L (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
FI922903A0 (fi) 4-acetoxipiperidin derivat, deras framstaellningsfoerfarande och anvaendning som antagonist foer muskarina m-3 receptorer.
NO974205D0 (no) Heterocyklisk-substituerte piperazinonderivater som tachykininreceptor-antagonister
FI943359A (fi) Atsasykliset-heterosykliset yhdisteet angiotensiini II reseptoriantagonisteina
FI941118A0 (fi) Bentsyyli-imidatsopyridiinijohdannainen angiotensiini II reseptoriantagonistina
FI941117A0 (fi) Bentsyyli-imidatsopyridiinijohdannaiset angiotensiini II reseptoriantagonisteina
ZA9600758D (en) Idole derivatives as 5-ht receptor antagonist.
NO963775L (no) Indol-derivater som CCK-reseptorantagonister
FI924789A0 (fi) Gamma-interferoners loesliga, stympade receptor
DK0940391T3 (da) Quinolinderivater som tachykinin-NK3-receptor-antagonister
ITBO910231V0 (it) macchina spaccafondelli per edilizia.
FI924721A (fi) 2,3-dideoxy-4-tioribonukleosider som antivirala aemnen